First look at clinical trial data suggests donanemab may work better than similar-acting rival, but company acknowledges deaths and serious brain side effects
Elizabeth Blackburn cuts short her tenure at Salk amid gender discrimination lawsuits, which have also led Inder Verma to take leave of absence from editor-in-chief of PNAS